Search jobs 09-Mar-2021 Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE marks T-SPOT ®. COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 8 th, 2021 – Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announced that today it has released the T-SPOT. COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test.